2021
Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2012
Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate
Nault A, Peipert J, Zhao Q, Madden T, Secura G. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate. American Journal Of Obstetrics And Gynecology 2012, 208: 48.e1-48.e8. PMID: 23103344, PMCID: PMC3974101, DOI: 10.1016/j.ajog.2012.10.876.Peer-Reviewed Original Research
2011
Continuation and Satisfaction of Reversible Contraception
Peipert J, Zhao Q, Allsworth J, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and Satisfaction of Reversible Contraception. Obstetrics And Gynecology 2011, 117: 1105-1113. PMID: 21508749, PMCID: PMC3548669, DOI: 10.1097/aog.0b013e31821188ad.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildContraceptionContraceptive Agents, FemaleContraceptive Devices, FemaleContraceptives, OralFemaleFollow-Up StudiesHumansIntrauterine DevicesKaplan-Meier EstimateMiddle AgedPatient SatisfactionProportional Hazards ModelsProspective StudiesTime FactorsTransdermal PatchYoung AdultConceptsOral contraceptive pillsIntrauterine deviceReversible contraception methodsContinuation ratesReversible contraceptionContraception methodsContraceptive methodsFirst-line contraceptive methodReversible contraception usersProspective cohort studyHigh contraceptive efficacyMonths of enrollmentDepot medroxyprogesterone acetateLevonorgestrel intrauterine systemCopper intrauterine deviceContraceptive CHOICE ProjectHigh rateSurvey time pointsCohort studyIntrauterine systemContraceptive pillsMedroxyprogesterone acetateOCP usersContraceptive efficacyHormonal methods
2009
Rates of Follow-up and Repeat Pregnancy in the 12 Months After First-Trimester Induced Abortion
Madden T, Westhoff C. Rates of Follow-up and Repeat Pregnancy in the 12 Months After First-Trimester Induced Abortion. Obstetrics And Gynecology 2009, 113: 663-668. PMID: 19300332, DOI: 10.1097/aog.0b013e318195dd1e.Peer-Reviewed Original ResearchConceptsDepot medroxyprogesterone acetateRepeat pregnancyElective abortionFirst-trimester elective abortionFirst-trimester surgical abortionLate groupInjectable depot medroxyprogesterone acetateHistorical cohort studyMultivariable logistic regressionHospital patient databaseTime groupsHospital-based familyTime of abortionProportion of womenCohort studyPatient characteristicsRoutine followMultivariable analysisMedroxyprogesterone acetateImmediate administrationFollow-upSurgical abortionClinical dataMedical CenterPregnancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply